Sugi Predict

Sugi Predict / Compounds / SCHEMBL299296

SCHEMBL299296

SCHEMBL299296

NC1Cc2ccccc2C(c2ccccc2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 12/20 1.00
▸ SLC6A2 P23975 4/20 0.65
▸ SLC6A4 P31645 4/20 0.65
▸ SLC6A3 Q01959 4/20 0.65
▸ HTR2A P28223 2/20 0.58
▸ HTR2C P28335 2/20 0.58
▸ HTR2B P41595 2/20 0.58
▸ HRH3 Q9Y5N1 2/20 0.58
▸ MTNR1A P48039 1/20 0.48
▸ MTNR1B P49286 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12998412 1.00 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL9903945 1.00 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL299351 1.00 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL30584623 1.00 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL9903949 1.00 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
Hydrochloric Acid SCHEMBL9731477 0.98 SIGMAR1 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL16687781 0.82 SIGMAR1 (0.70) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL11881965 0.80 SIGMAR1 (0.66) SIGMAR1SLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL814886 0.79 SLC6A2 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3CYP3A4
SCHEMBL814887 0.79 SLC6A2 (1.00) SIGMAR1SLC6A2SLC6A4SLC6A3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370497-A1 SEROTONIN 5-HT2A, 5-HT2B, AND 5-HT2C RECEPTOR INVERSE AGONISTS Northeastern University (US) 2024-05-22 — — EP disclosed
CN-117730073-A Serotonin 5-HT2A, 5-HT2B and 5-HT2C receptor inverse agonists 东北大学 2024-03-19 — — CN disclosed
WO-2023288027-A1 SEROTONIN 5-HT2A, 5-HT2B, AND 5-HT2C RECEPTOR INVERSE AGONISTS NORTHEASTERN UNIVERSITY (US) 2023-01-19 — — WO disclosed
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2018-07-10 — — US disclosed
US-9422229-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-08-23 — — US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 — — US disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 — — US disclosed
EP-2164324-B1 THERAPEUTIC COMPOUNDS UNIV FLORIDA (US) 2014-08-13 — — EP disclosed
US-20140155490-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-06-05 — — US disclosed
US-8586634-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2013-11-19 — — US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 — — US disclosed
EP-2427183-A2 THERAPEUTIC COMPOUNDS University of Florida Research Foundation, Inc. (US) 2012-03-14 — — EP disclosed
US-20100305212-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-12-02 — — US disclosed
WO-2010129048-A2 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-11-11 — — WO disclosed
EP-2164324-A1 THERAPEUTIC COMPOUNDS University Of Florida Research Foundation (US) 2010-03-24 — — EP disclosed
WO-2009061436-A1 COMPOUND FOR ACTIVATING 5-HT2C RECEPTORS IN COMBINATION WITH AN AMPHETAMINE COMPOUND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2009-05-14 — — WO disclosed
WO-2008156707-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2008-12-24 — — WO disclosed
US-5151446-A Neurological disorders or cardiovascular disorders NORTHWESTERN UNIVERSITY (US) 1992-09-29 — — US disclosed
US-5071875-A Nervous system, psychological disorders; sleep cycle, skin dis coloration NORTHWESTERN UNIVERSITY (US) 1991-12-10 — — US disclosed
EP-0420064-A2 Substituted 2-amidotetralins as melatonin agonists and antagonists NORTHWESTERN UNIVERSITY (US) 1991-04-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 SIGMAR1 1254/4885SLC6A2 266/4885SLC6A4 83/4885
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds HTR2C, HTR2A, HTR3C SIGMAR1 1155/4885SLC6A2 184/4885SLC6A4 54/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 SIGMAR1 1254/4885SLC6A2 266/4885SLC6A4 83/4885
US-20140155490-A1 THERAPEUTIC COMPOUNDS HTR2C, HTR3B, HTR2A SIGMAR1 729/4885SLC6A2 121/4885SLC6A4 42/4885
US-20100305212-A1 THERAPEUTIC COMPOUNDS HTR2C, HTR3B, HTR2A SIGMAR1 729/4885SLC6A2 121/4885SLC6A4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.